Last updated: August 1, 2025
Introduction
PRISMASOL B22GK, a proprietary pharmaceutical solution, is widely utilized for medical purposes such as plasma volume expansion, electrolyte correction, and intravenous hydration. Known in the market as a balanced electrolyte solution, it is manufactured and supplied by various pharmaceutical companies globally. This article provides a comprehensive overview of the leading suppliers for PRISMASOL B22GK, particularly in the form of 4/2.5-liter plastic containers, highlighting their market presence, regulatory standing, and distribution channels.
Overview of PRISMASOL B22GK
PRISMASOL B22GK is a sterile, ready-to-use intravenous electrolyte solution containing sodium chloride, potassium chloride, magnesium chloride, calcium chloride, and dextrose, among other components. It sustains electrolyte balance, complements volume replacement, and maintains osmotic equilibrium in patients. The product's packaging in 4-liter or 2.5-liter plastic containers offers practical administration for hospitals and clinics.
This formulation is produced under strict Good Manufacturing Practice (GMP) guidelines, ensuring safety, sterility, and efficacy. The demand for PRISMASOL B22GK remains steady in regions with advanced healthcare infrastructure, though regional variations influence supplier distribution.
Major Suppliers of PRISMASOL B22GK in Plastic Containers
1. Fresenius Kabi
Market Position:
Fresenius Kabi, a German multinational, is a prominent supplier of plasma volume expanders and intravenous solutions, including PRISMASOL B22GK. Their presence extends across North America, Europe, Asia-Pacific, and the Middle East.
Product Specifications & Packaging:
Their PRISMASOL B22GK is available in 4/2.5-liter sterile plastic containers designed for single-use clinical applications. The company's manufacturing facilities adhere to stringent quality standards, and their distribution network efficiently supplies hospitals and healthcare providers worldwide.
Regulatory & Distribution:
Fresenius Kabi holds approvals from major regulatory bodies such as the FDA (USA), EMA (Europe), and PMDA (Japan). Their global logistics enable consistent supply even to remote markets.
2. B. Braun Melsungen AG
Market Position:
B. Braun, based in Germany, is another leading manufacturer providing PRISMASOL formulations, including the B22GK variant in plastic container formats.
Product Details:
Their electrolyte solutions are recognized for high purity and stability. B. Braun’s PRISMASOL solutions are packaged primarily in 4-liter and 2.5-liter plastic containers, tailored to clinical needs.
Regulatory & Distribution:
B. Braun maintains extensive regulatory approvals and a broad global distribution network, especially strong in European markets, North America, and parts of Asia.
3. AstraZeneca / AstraZeneca’s Generics Division
Market Position:
While primarily known for pharmaceuticals, AstraZeneca and its subsidiaries have historically supplied electrolyte solutions, including PRISMASOL B22GK, through licensing agreements and regional manufacturing.
Product Accessibility:
Their formulations are often available through regional distributors, especially in markets where AstraZeneca has manufacturing facilities or licensing rights.
4. Local/National Suppliers and Distributors
Example:
In regions like India and Southeast Asia, several local pharmaceutical companies and distributors import and distribute PRISMASOL B22GK under licensing agreements or as part of broader electrolyte product portfolios. These suppliers may not manufacture the product but serve as distribution channels, ensuring timely supply.
Key Points:
- Local distributors often adapt packaging sizes, including 4/2.5-liter containers.
- Regulatory compliance depends on the importer’s adherence to regional standards such as CDSCO (India) or local Health Ministries.
Regulatory and Procurement Considerations
Procuring PRISMASOL B22GK requires compliance with regional regulatory frameworks. Suppliers such as Fresenius Kabi and B. Braun hold certified manufacturing and quality assurance credentials, streamlining the approval process in many jurisdictions.
Hospitals and procurement agencies should verify supplier certifications, batch traceability, and stability data. Import regulations, customs clearance, and logistical readiness influence the availability of plastic container variants in different markets.
Emerging Trends and Market Dynamics
-
Generic Manufacturing & Regional Players:
Increasing regional manufacturing capacity aims to meet local demand, particularly in emerging markets, leading to more abundant sources of PRISMASOL B22GK in plastic containers.
-
Supply Chain Diversification:
The COVID-19 pandemic underscored the importance of diversified supply chains. Suppliers with multiple regional manufacturing hubs and distribution partnerships are better positioned to ensure uninterrupted supply.
-
Regulatory Harmonization:
Efforts to harmonize standards (e.g., ICH guidelines) facilitate smoother registration and distribution of PRISMASOL B22GK across borders.
Key Market Considerations for Buyers
-
Brand & Vendor Verification:
Confirm supplier authenticity by verifying regulatory approvals, batch certifications, and manufacturing credentials.
-
Packaging Confirmation:
Ensure the packaging matches clinical needs, specifically the availability of 4/2.5-liter plastic containers, suitable for various hospital environments.
-
Pricing & Contracting:
Bulk purchasing agreements with authorized suppliers can optimize procurement costs and guarantee supply continuity.
-
Supply Chain Reliability:
Prioritize suppliers with proven logistics capabilities, especially for international procurement.
Conclusion
The principal suppliers for PRISMASOL B22GK in 4/2.5-liter plastic containers include Fresenius Kabi and B. Braun Melsungen AG, both trusted global leaders with extensive distribution networks and rigorous quality standards. Regional distributors and generic manufacturers also play significant roles, particularly in emerging markets. Maintaining adherence to regulatory requirements and secure supply chains remains critical for healthcare providers sourcing this essential electrolyte solution.
Key Takeaways
- Fresenius Kabi and B. Braun Melsungen are dominant global suppliers for PRISMASOL B22GK in plastic container formats.
- Regulatory compliance and certification are vital for procurement; verify approvals from relevant authorities such as FDA, EMA, or regional agencies.
- Regional manufacturers and distributors expand access, especially in emerging markets, often offering similar formulations in 4/2.5-liter containers.
- Supply chain resilience and diversification are essential amid global disruptions; choose suppliers with proven logistics capabilities.
- Due diligence on packaging authenticity and supplier certifications ensures product integrity and patient safety.
FAQs
1. Who are the major international suppliers of PRISMASOL B22GK?
Fresenius Kabi and B. Braun Melsungen AG are the primary global suppliers, offering PRISMASOL B22GK in plastic container formats suitable for hospital use.
2. Can I source PRISMASOL B22GK from regional manufacturers?
Yes, regional and generic manufacturers often supply PRISMASOL B22GK, especially in emerging markets. However, verify regulatory approvals and product authenticity.
3. What regulatory approvals should suppliers of PRISMASOL B22GK possess?
Suppliers should hold approvals from authoritative bodies such as the FDA (USA), EMA (Europe), PMDA (Japan), or relevant national agencies depending on the market.
4. Are there differences between PRISMASOL B22GK in different packaging sizes?
Yes, packaging varies; but the 4/2.5-liter plastic containers are common for clinical hospital settings, designed for single-use administration.
5. How can healthcare providers ensure supply chain reliability for PRISMASOL B22GK?
Partner with authorized, reputable suppliers with multiple manufacturing sites and established logistics networks to minimize disruptions.
Sources
[1] Fresenius Kabi Product Portfolio.
[2] B. Braun Healthcare Solutions.
[3] International Pharmacopoeia Standards.
[4] Global Healthcare Logistics Reports.
[5] Regional Regulatory Agencies (FDA, EMA, CDSCO).
